{"id":47218,"date":"2024-10-30T16:39:16","date_gmt":"2024-10-30T11:09:16","guid":{"rendered":"https:\/\/www.equentis.com\/blog\/?p=47218"},"modified":"2024-10-31T13:37:00","modified_gmt":"2024-10-31T08:07:00","slug":"wockhardts-molecule-drives-5x-stock-increase-in-1-year","status":"publish","type":"post","link":"https:\/\/www.equentis.com\/blog\/wockhardts-molecule-drives-5x-stock-increase-in-1-year\/","title":{"rendered":"Wockhardt’s Molecule Drives 5x Stock Increase in a Year: 25 Years of Research Pays Off"},"content":{"rendered":"
<\/div>\n

The pharmaceutical industry is no stranger to long-term investments<\/a> in research and development (R&D). One of India\u2019s prominent pharmaceutical companies, Wockhardt, witnessed an unprecedented stock surge, climbing fivefold due to the success of a unique molecule developed over 25 years. <\/p>\n\n\n\n

In July, Wockhardt’s new drug Zaynich, an antibiotic targeting highly resistant infections, helped treat a challenging infection in a young cancer patient in California. News of Zaynich\u2019s successful trials is already boosting Wockhardt\u2019s stock price<\/a>, with some investors making long-term bets on the company.<\/p>\n\n\n\n

\"\"
Source: <\/strong>NSE<\/strong><\/a><\/figcaption><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Wockhardt\u2019s shares have struggled, underperforming the Nifty<\/a> 50 by over 150% over the past decade, impacting its reputation as an investment. However, its recent breakthrough antibiotic drug has sparked interest from mutual funds<\/a> and prominent investors. <\/p>\n\n\n\n

Mutual funds and high-net-worth investors like Rekha Jhunjhunwala<\/a> were among the first to spot the opportunity. The stock has surged 5x in a year to over INR 1,100 per share, yet the company\u2019s financial struggles persist. It has reported losses for 11 straight quarters, its return ratios have declined for over a decade, and its sales growth remains highly inconsistent.<\/p>\n\n\n\n

\"\"
Source: Economic Times<\/a><\/figcaption><\/figure>\n\n\n\n

<\/p>\n\n\n\n

For Wockhardt chairman Habil Khorakiwala, it was a wait spanning over two decades. His first antibiotic, WCK771, began its journey in 2000, with Zaynich standing out as a promising lead that his scientists were hopeful about.<\/p>\n\n\n\n

What is Zaynich<\/strong><\/h2>\n\n\n\n

It is an antibiotic designed to combat bacterial infections that have developed significant resistance to other treatments. Known as WCK5222 or Zaynich, this unassuming drug has captured the attention of investors. Wockhardt now has an opportunity to reclaim its former glory.<\/p>\n\n\n\n

WCK 5222: Zaynich<\/strong><\/h3>\n\n\n\n
Indication Potential<\/strong>
-Complicated Urinary Tract Infections

-Complicated Intra-abdominal InfectionsBlood Stream Infections
<\/td>		WCK 5222<\/strong>
-Patents: Compound & Composition patent, granted in key markets.

-Qualified Infectious Disease Product status granted by USFDA

-Key opinion leaders from US, EU & China.<\/td><\/tr>
Treatment Regimen<\/strong>
-Hospital Injectible

-TID for 7-14 Days<\/td>		WCK 5222<\/strong>
-Patents: Compound & Composition patent, granted in key markets.

-Qualified Infectious Disease Product status granted by USFDA

-Key opinion leaders from the US, EU & China.<\/td><\/tr><\/tbody><\/table>
Source: Economic Times<\/a><\/figcaption><\/figure>\n\n\n\n

<\/p>\n\n\n\n

The Financial Impact: Why Wockhardt\u2019s Stock Surged<\/strong><\/h3>\n\n\n\n